# A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02)

> **NCT07684612** · PHASE3 · RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 690 (estimated)

## Conditions studied

- Ovarian Neoplasms

## Interventions

- **DRUG:** Mocertatug rezetecan (Mo-Rez)
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **DRUG:** Gemcitabine
- **DRUG:** Pegylated liposomal doxorubicin (PLD)
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT07684612
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09-08
- **Primary completion:** 2030-05-21
- **Final completion:** 2033-04-22
- **Target enrollment:** 690 (ESTIMATED)
- **Last updated:** 2026-10-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07684612

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07684612, "A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07684612. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*